(The Obesity Society)
- Obesity is a chronic disease affecting over 100 million Americans. Despite its prevalence and serious health consequences, widespread insurance barriers limit access to FDA-approved GLP-1 treatments.
Fortunately, that may be changing. The Trump administration and FDA-approved GLP-1 manufacturers recently announced a partnership to expand access to these potentially life-saving medications by lowering monthly prices to $299 for cash-pay patients and covering millions of Medicare patients with a $50 monthly copay. It’s time for states—who, under the deal, can purchase FDA-approved GLP-1s on the same terms as Medicare—and private insurers to step up and do their part by covering these treatments. Otherwise, some patients may continue to turn to unsafe compounded GLP-1 knockoffs.
Patient Safety Is at Risk
Compounding is meant to be a narrow solution for those with unique medical needs that cannot be met by FDA-approved medicines. But large-scale compounders are unlawfully selling mass-produced GLP-1 knockoffs that are not vetted by the FDA for safety, efficacy, or quality and often include untested changes—posing a serious public health risk.
For instance, some compounders are adding ingredients like B12 without medical indication and falsely claiming their products are personalized, when in fact they are making the same changes to all their unapproved knockoffs without regard to patient need. These knockoffs carry significantly higher risks, including over twice the rate of hospitalization.
Access to FDA-approved GLP-1s Is More Important Than Ever
Obesity management medications are critical interventions for a serious chronic disease that is related to several other health conditions, and they can help reduce long-term spending on the many costly health complications associated with obesity. This is why it is critical that states, employers, and commercial insurers expand coverage for FDA-approved treatments.
Meanwhile, patients should take precautions by speaking with a trusted healthcare provider and avoiding risky compounded products that falsely claim to be proven safe and effective.
For credible, science-based guidance on comprehensive obesity care, visit www.obesity.org.
